Skip to main content

Lumakras

Generic name: sotorasib
Dosage form: tablets
Drug class: Miscellaneous antineoplastics

Medically reviewed by Judith Stewart, BPharm. Last updated on Sep 21, 2023.

What is Lumakras?

Lumakras is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC):

Your healthcare provider will perform a test to make sure that Lumakras is right for you.

It is not known if this medicine is safe and effective in children.

Before taking Lumakras

Before you start treatment, tell your healthcare provider about all your medical conditions, including if you:

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, dietary and herbal supplements. Lumakras can affect the way some other medicines work, and some other medicines can affect the way Lumakras works.

Especially tell your healthcare provider if you take antacid medicines, including Proton Pump Inhibitor (PPI) medicines or H2 blockers during treatment. Ask your healthcare provider if you are not sure.

How should I take Lumakras?

Lumakras side effects

Lumakras may cause serious side effects, including:

The most common side effects include:

These are not all the possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Amgen at 1-800-772-6436 (1-800-77-AMGEN).

What other drugs will affect Lumakras?

Sometimes it is not safe to use certain medications at the same time. Some drugs can affect your blood levels of other drugs you take, which may increase side effects or make the medications less effective.

Other drugs may interact with sotorasib, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

How should I store Lumakras?

Keep all medicines out of the reach of children and pets.

General information about the safe and effective use of Lumakras.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use this medicine for a condition for which it was not prescribed. Do not give it to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information that is written for healthcare professionals.

What are the ingredients in Lumakras?

Active Ingredient: sotorasib
Inactive Ingredients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium
stearate. Tablet film coating material contains polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and iron oxide yellow.

Popular FAQ

You will take Lumakras until your disease worsens or you have side effects that you cannot tolerate. Your doctor may be able to adjust your dose if you experience side effects like liver or lung toxicity, severe nausea or vomiting, severe diarrhea or other side effects. In some cases, you may need to stop treatment, as determined by your doctor.

Yes, Lumakras has an orphan drug designation from the FDA for KRAS G12C-positive NSCLC and colorectal cancer. It also holds a breakthrough therapy designation in the US and China.

Orphan drugs are medicines developed to help treat, prevent or diagnose rare “orphan” diseases, which are conditions that each affect fewer than 200,000 people in the United States. Companies that embark on developing orphan drugs get tax incentives, subsidies for clinical research, and the exclusive right to market the drugs for seven years.

In one clinical study with Lumakras, 45 out of 124 people (36%) saw their non-small cell lung cancer (NSCLC) tumors disappear or decrease in size by at least 30%.The median duration of response was 10 months. In another study, the 12-month progression-free survival rate was 24.8% with Lumakras vs. 10.1% with the chemotherapy agent docetaxel. Continue reading

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.